Recombinant Human herpesvirus 2 Envelope glycoprotein E (gE)

What is HSV-2 glycoprotein E and how is it processed in infected cells?

HSV-2 glycoprotein E (gE2) is a viral envelope protein expressed on the surface of virions and infected cells . It exists as a heterodimer with glycoprotein I (gI) and undergoes complex processing in infected cells. The gE precursor protein is cotranslationally glycosylated, generating a high-mannose intermediate which is subsequently cleaved during processing . This cleavage results in a secreted amino-terminal portion and a cell- and virion-associated, heavily O-glycosylated carboxy-terminal portion that constitutes the mature gE-2 . This processing pathway is critical for the functional properties of gE in viral pathogenesis.

What are the primary functions of HSV-2 gE in viral pathogenesis?

HSV-2 gE serves two main functions during viral infection. First, the gE/gI heterodimer is responsible for facilitating cell-to-cell spread of the virus, enabling infection to progress without exposing virions to the extracellular environment . Second, gE2 functions as an immune evasion molecule by binding to the Fc domain of immunoglobulin G (IgG) . This binding inhibits immunological activities facilitated by the IgG Fc domain through a process described as antibody bipolar bridging . This mechanism effectively shields the virus from Fc-mediated immune responses, including viral neutralization and antibody-dependent cellular cytotoxicity .

How does HSV-2 gE differ structurally and functionally from HSV-1 gE?

While both HSV-1 gE (gE-1) and HSV-2 gE (gE-2) share similar functions, there are notable differences in their binding properties. Research has shown that HSV-1 gE is capable of binding IgG Fc as a monomer and in a heterodimeric complex with gI, with the heterodimer having 50- to 100-fold greater affinity for Fc than gE alone . In contrast, characterization of soluble gE-2 by surface plasmon resonance (SPR) demonstrates that it is incapable of binding human IgG or the IgG Fc domain independently . This suggests that gE-2 may have stricter requirements for heterodimer formation with gI to functionally bind IgG, representing a significant difference between the two viral types.

How does HSV-2 gE contribute to immune evasion?

HSV-2 gE2 functions as an immune evasion molecule by binding the IgG Fc domain . This binding activity inhibits immunologic activities facilitated by the IgG Fc domain through antibody bipolar bridging . In this process, the Fab portion of an antibody binds to its target antigen while the Fc portion is simultaneously bound by gE, effectively neutralizing the effector functions of the antibody . HSV-2 gE2 has been demonstrated to be synergistic with another viral glycoprotein, gC2, in protecting the virus from antibody and complement neutralization . Together, these mechanisms allow HSV-2 to effectively evade host immune responses despite the presence of circulating neutralizing antibodies.

What methodological approaches can be used to study gE-mediated immune evasion?

Researchers can employ several experimental approaches to study gE-mediated immune evasion:

• Surface plasmon resonance (SPR) assays to characterize the binding kinetics between soluble forms of gE/gI and IgG Fc domains .

• Production of soluble forms of HSV-2 gE and gE/gI heterodimers for in vitro binding studies .

• Neutralization assays comparing wild-type virus with gE-negative variants to assess the contribution of gE to antibody evasion .

• Antibody-dependent cellular cytotoxicity (ADCC) assays to evaluate how gE affects Fc-mediated effector functions .

• Generation of antibodies against gE2 to block gE2-mediated IgG Fc binding and assess the impact on viral spread .

These methodologies provide complementary approaches to dissect the specific mechanisms by which gE contributes to immune evasion.

What expression systems are optimal for producing recombinant HSV-2 gE?

Based on current research approaches, recombinant HSV-2 gE can be effectively produced in several expression systems, each with distinct advantages:

• Mammalian cell expression systems (such as Chinese hamster ovary cells or HEK293 cells) provide appropriate post-translational modifications, particularly the complex O-glycosylation patterns essential for mature gE-2 function .

• Baculovirus expression systems in insect cells offer higher yields while maintaining most post-translational modifications.

• Bacterial expression systems can be used for producing non-glycosylated fragments for structural studies, though these may lack functional activity.

For studies requiring fully functional gE2, mammalian expression systems are preferred as they ensure proper processing, including the cleavage of the gE2 precursor into the secreted amino-terminal portion and the cell-associated, heavily O-glycosylated carboxy-terminal mature gE-2 .

How can researchers verify the proper expression and folding of recombinant gE2?

Verification of proper expression and folding of recombinant gE2 can be accomplished through:

• Western blot analysis using type-specific anti-gE2 monoclonal antibodies to confirm the expected molecular weight and processing .

• Enzyme immunoassay (EIA) on cells expressing recombinant gE2 using multiple anti-gE2 monoclonal antibodies targeting different epitopes .

• Functional binding assays to verify IgG Fc binding capacity, particularly when expressed as a heterodimer with gI .

• Glycosylation analysis to confirm proper O-glycosylation of the mature protein .

• Immunofluorescence microscopy to verify cellular localization patterns consistent with native gE2.

Researchers should employ multiple verification methods, as phenotypic expression differences have been observed among clinical isolates, including rare gG-2-negative variants .

Why is gE2 considered a potential vaccine target for HSV-2?

HSV-2 gE2 is considered a promising vaccine target for several reasons:

• It functions as an immune evasion molecule, and neutralizing this function could enhance natural immune responses against the virus .

• Antibodies produced by immunization with gE2 have been shown to block gE2-mediated IgG Fc binding and cell-to-cell spread .

• When combined with other viral glycoproteins in multivalent vaccines, gE2 significantly improves protection compared to single-antigen approaches .

• It represents a strategic approach that targets both viral entry (when combined with entry proteins like gD2) and immune evasion mechanisms .

Research has demonstrated that a trivalent vaccine containing gE2, gC2, and gD2 provided superior protection compared to gD2 alone in animal models, particularly in protecting dorsal root ganglia (DRG) from infection .

What evidence supports the efficacy of multivalent vaccines including gE2?

Studies have provided compelling evidence for the efficacy of multivalent vaccines that include gE2:

• When gE2 was added to gC2/gD2 to form a trivalent vaccine, neutralizing antibody titers with and without complement were significantly higher than those produced by gD2 alone .

• The trivalent vaccine protected the dorsal root ganglia (DRG) of 32/33 (97%) mice between days 2 and 7 post-challenge, compared with 27/33 (82%) in the gD2 group .

• HSV-2 DNA copy numbers were significantly lower in mice immunized with the trivalent vaccine than in those immunized with gD2 alone .

• The protection offered by the trivalent vaccine exceeded what was previously reported for gC2/gD2 immunization .

These findings provide a strong rationale for including gE2 in multivalent subunit vaccines designed to block HSV-2 immune evasion mechanisms.

How can immunodominant epitopes in HSV-2 gE be identified?

Identifying immunodominant epitopes in HSV-2 gE can be accomplished through several methodological approaches:

• Using overlapping peptide sets spanning the entire gE2 sequence and testing for recognition by patient T-cells, similar to approaches used for gD2 .

• Employing 51Cr-release cytotoxicity and IFN-γ ELISPOT assays to assess T-cell responses to peptide epitopes .

• Fine mapping of responses using panels of internal overlapping peptides within identified immunoreactive regions .

• Combining MHC typing with direct in vitro binding assays of peptides to individual MHC molecules to identify restriction elements .

• Comparing recognition patterns between HSV-1+ and HSV-2+ subjects to identify type-specific versus cross-reactive epitopes .

These approaches can reveal multiple epitopes within single peptide regions and demonstrate promiscuous binding of individual peptides to multiple MHC types, providing critical information for vaccine design .

What is known about cross-recognition between HSV-1 and HSV-2 glycoproteins?

Cross-recognition between HSV-1 and HSV-2 glycoproteins has important implications for immunity and vaccine development:

Understanding these cross-recognition patterns is essential for developing vaccines that might provide protection against both HSV types or leverage existing immunity to one type to enhance protection against the other.

How do gE-based vaccines compare to other herpes vaccine approaches?

Glycoprotein E-based vaccines represent one approach among several strategies for herpes vaccines:

• Recombinant varicella zoster virus (VZV) glycoprotein E antigen vaccines, such as Shingrix, have demonstrated high efficacy against herpes zoster (shingles), with protection not declining with age, unlike live attenuated vaccines .

• For HSV-2, subunit vaccines targeting only virus entry molecules (like gD2 alone) have failed to prevent genital herpes in human trials .

• The novel approach of combining entry molecules (gD2) with immune evasion molecules (gC2 and gE2) has shown superior efficacy in animal models compared to single-antigen approaches .

• Recombinant glycoprotein E vaccines do not contain live virus and may therefore be suitable for immunocompromised patients, pending further studies .

The data suggests that multivalent approaches targeting both viral entry and immune evasion mechanisms may be more effective than traditional single-antigen vaccines for preventing HSV infections.

What are the most significant challenges in studying HSV-2 gE variants?

Research on HSV-2 gE variants faces several significant challenges:

• Clinical isolates of HSV-2 occasionally exhibit phenotypic variations in gE expression, including rare gE-negative variants, complicating standardization of experimental systems .

• The molecular mechanism underlying the lack of expression can vary, with some isolates harboring frameshift mutations leading to complete or partial inactivation of the gE gene .

• The conservation of gE-2 among clinical HSV-2 isolates is essential for reliable serological determination of gE-2-specific antibodies, but variations can occur .

• Distinguishing between mutations affecting expression versus those affecting epitope recognition by specific antibodies requires multiple methodological approaches .

• The rarity of clinical HSV mutants lacking dispensable gene products like gE-2 suggests important but incompletely understood functions in natural infection .

These challenges highlight the importance of using multiple complementary techniques when studying gE variants and interpreting results in the context of the complex biology of HSV-2.

What are promising future directions for research on HSV-2 gE?

Several promising research directions could advance our understanding of HSV-2 gE and its applications:

• Structural studies comparing HSV-1 and HSV-2 gE/gI complexes to understand the molecular basis for their different IgG binding properties .

• Development of small molecule inhibitors targeting gE-mediated immune evasion as a novel therapeutic approach.

• Investigation of the role of gE in establishing and maintaining latency in sensory neurons.

• Studies on the long-term efficacy of multivalent vaccines containing gE2, particularly regarding protection from latent infection .

• Research on how natural variations in gE across clinical isolates impact pathogenesis and immune evasion.

These research directions could lead to improved vaccine candidates and novel therapeutic approaches for HSV-2 infections.

How might gE-targeting strategies be combined with other approaches for optimal control of HSV-2 infection?

Optimal control of HSV-2 infection might be achieved through combined approaches:

• Multivalent vaccines containing gE2, gC2, and gD2 have already demonstrated superior protection in animal models compared to gD2 alone .

• Combining vaccine approaches with antiviral drugs could provide both preventive and therapeutic benefits.

• Immunomodulatory strategies that enhance specific immune responses against HSV-2 while blocking viral immune evasion mechanisms could be synergistic.

• Development of topical microbicides containing gE-neutralizing antibodies along with entry inhibitors could provide local protection against transmission.

• Therapeutic vaccines containing gE2 might boost immunity in already infected individuals, potentially reducing recurrence frequency or severity.

The complexity of HSV-2 pathogenesis and immune evasion suggests that combined approaches targeting multiple aspects of the viral life cycle will likely be most effective for prevention and control.